CELL INTELLIGENCE · 肿瘤细胞治疗研究

局部晚期头颈部鳞状细胞癌免疫治疗-放疗/化疗联合方案中的耐药机制

Resistance Mechanisms in Immunotherapy-Radiotherapy/Chemotherapy Combinations in Locally Advanced Head & Neck Squamous Cell Carcinoma.

EGFR/HER2 双靶点 CAR-NK 细胞治疗复发或转移性头颈部鳞状细胞癌

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

这是一项 I/II 期、非随机的注册临床试验，评估 HER2NK 细胞治疗头颈部鳞癌的疗效与安全性。研究设计：非随机。当前状态：招募中。计划入组 42 例。试验地点：中国 · 深圳（共 1 个中心，其中中国 1 个）。登记号：NCT07617805。

靶向头颈部鳞状细胞癌中的 NKG2D 轴：从分子机制到临床应用

Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications.

头颈部鳞状细胞癌 CAR-T 细胞治疗的进展与挑战

Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.

探索 CAR-NK 细胞治疗在头颈部癌（HNC）管理中的潜力：叙述性综述

Exploring the potential of CAR-NK cell therapy in the management of head and neck cancer (HNC): a narrative review.

CAR-NK 细胞通过将靶向细胞毒作用与更优的安全性特征相结合，为 HNSCC 提供了新的治疗途径。

头颈部鳞状细胞癌中放疗和靶向治疗与 NK 细胞免疫治疗的联合效应

Combination Effect of Radiotherapy and Targeted Therapy with NK Cell-Based Immunotherapy in head and Neck Squamous Cell Carcinoma.

本研究提示，西妥昔单抗、放疗与 NK 细胞联合的多模式方案可显著提高头颈部鳞状细胞癌（HNSCC）的治疗疗效，提供了一种新颖且有前景的治疗策略。

NK 细胞：头颈部鳞状细胞癌免疫治疗的未来之星

Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.

探索 Amivantamab 联合 Pembrolizumab 在肺和头颈部鳞状细胞癌中的免疫调节作用

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.

靶向 HER1 (EGFR) 的 CAR-NK 细胞对头颈部鳞状细胞癌 (HNSCC) 显示高效抗肿瘤活性

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC).

BCA101 是一种肿瘤靶向双功能融合抗体，可同时抑制 EGFR 和 TGFβ信号传导，从而持久抑制肿瘤生长

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.